EyePoint, Inc.
EYPTAbout the company
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
3 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
All 10 investors flag EYPT's cash flow
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | NEUTRAL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-05 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-05 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-12 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-12 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Cash Flow0% pass✗ 12▾
All 10 investors flag EYPT's cash flow
Free Cash Flow Proxy$-232.9M✗BuffettPositive and growingFCF Positive and Growing$-299.1M✗LynchPositive and growingOperating Cash Flow$-240.1M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-65.97%, ROA=-63.73%✗PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-699.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive2/16 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-1156.6%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency3/16 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-299.1M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-859.19%; #4395/4519 (top 97.3%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✗ 13▾
All 8 investors flag EYPT's growth
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -21.1% vs Rev: -93.9%✗LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency2/17 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-6.0%✗Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -163.1% -> -776.0%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-1.8%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR-14.5% over 5 years✗Neff7%-20% annualized - Verdicts0% pass✗ 13▾
Split decision: 13 FAIL · 3 NEUTRAL
Overall verdict✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (1/3)✗AkreFAIL (0/6)✗MarksFAIL (1/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked) - Profitability6% pass✓ 2✗ 33▾
15 of 16 flag EYPT's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)2/22 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)2/22 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-55.8%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-776.0% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$-232.9M✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-315.7%✗Lynch> 15%EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-122.4%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-63.73%✗PiotroskiROA > 0ROA Change YoY-31.27% -> -63.73% (delta: -32.45%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-65.97%, ROA=-63.73%✗PiotroskiCFO/Assets > ROAGross Margin Change YoY✗PiotroskiImproved YoYPre-Tax Income / Revenue-738.5%✗Dreman>= 8%Net Income / Shareholders' Equity-315.7%✗Dreman> 12%Margin of SafetyP/B=0.1x✓PabraiP/B < 1.5 or P/E < 15Return on Equity-47.1% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency2/17 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-13642.0%✗Ackman>= 15%Net Income / Shareholders Equity-315.7%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-163.1% (2023) -> -776.0% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendrevenue flat/down, operating margin -163.1% -> -776.0%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-983.77%; #6062/6340 (top 95.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity-315.67%; #4995/5226 (top 95.6%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.1806; #4121/5884 (top 70.0%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR-14.5% over 5 years✗Neff7%-20% annualizedPositive Diluted-EPS Years0/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag EYPT's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest Coverage✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity✗Lynch< 0.33Cash - Long-term Debt✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 0.00%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities3.30✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt Levels✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-7376.8x, D/EBITDA=N/A✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Valuation8% pass✓ 9✗ 19▾
12 of 13 flag EYPT's valuation — Graham, Lynch, Greenblatt +9 more
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio0.1x✓Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise ValueN/A (EV <= 0)✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-122.4%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share0.1x✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)Valuation ReasonablenessOE Yield=-900.6%✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-699.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=0.1x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low100% of trailing low ($0.31)✓Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-983.77%; #6062/6340 (top 95.6%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+3.1164; #448/6449 (top 6.9%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share0.08x✓SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+259.0%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0741; #4456/5247 (top 84.9%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-859.19%; #4395/4519 (top 97.3%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-97.82%; #6104/6202 (top 98.4%)✗OshaughnessyTop 10% of eligible cross-section - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag EYPT's efficiency — Buffett, Greenblatt, Piotroski +3 more
Current Ratio3.30✓Graham>= 2.0ROIC (3-5 yr avg)-214.3%✗Buffett> 10%ROIC - WACC-224.3%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-122.4%✗Greenblatt> 25%Current Ratio Change YoY7.81 -> 8.88✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.10x -> 0.09x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities3.30✓Dreman> 1.5Return on Invested Capital✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/2 years above 12% (latest -57.8%)✗SleepROIC > 12% in a majority of years
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 21.4% of shares last year, 67.4% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $34.8Mcurrent | -- | -- | -- | $1.1Best. | $525.8Mest. | $1.3Best. | $159.8Mest. | $319.0Mest. |
| Revenue | $2.6M↓94% | $756.0K↓22% | $507.0K↓90% | $696.0K↓97% | $31.4M↓28% | $43.3M↓6% | $46.0M↑11% | $41.4M↑12% | $36.9M |
| Operating Income | -$351.8M↓61% | -$96.9M↓56% | -$97.4M↓56% | -$87.2M↓79% | -$243.4M↓67% | -$145.9M↓94% | -$75.1M↑25% | -$99.6M↓80% | -$55.3M |
| Net Income | -$342.5M↓66% | -$95.6M↓60% | -$94.5M↓59% | -$84.8M↓88% | -$232.0M↓77% | -$130.9M↓85% | -$70.8M↑31% | -$102.3M↓75% | -$58.4M |
| EPS (Diluted) | -- | $-1.07↓26% | $-1.09↓28% | $-0.99↓52% | $-3.17↓37% | $-2.32↓27% | $-1.82↑34% | $-2.74↓35% | $-2.03 |
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | -13642.0%↓2546% | -12814.4%↓100% | -19207.1%↓1546% | -12532.5%↓6175% | -776.0%↓130% | -337.1%↓107% | -163.1%↑32% | -240.6%↓61% | -149.6% |
| ROE | -315.7%↓207% | — | — | — | -75.8%↓95% | -38.9%↓46% | -26.6%↑75% | -106.1%↓235% | -31.7% |
| Total Debt | -- | -- | -- | -- | -- | -- | -- | $39.8M↑9% | $36.6M |
| Shareholders' Equity | $108.5M↓46% | $108.5M↓46% | $166.4M↓32% | $230.5M↓23% | $306.1M↓9% | $336.5M↑26% | $266.3M↑176% | $96.4M↓48% | $184.4M |
| Current Ratio | 3.30↓54% | 3.30↓54% | 4.50↓44% | 6.66↓15% | 8.88↑14% | 7.81↑43% | 5.45↑9% | 5.00↓50% | 10.05 |
| Debt / Equity | — | — | — | — | — | — | — | 0.41↑108% | 0.20 |
| Operating Cash Flow | -$294.8M↓40% | -$86.8M↓46% | -$62.3M | -$80.5M↓52% | -$240.1M↓90% | -$126.2M↓6832% | $1.9M↑103% | -$65.0M↓30% | -$50.1M |
| Free Cash Flow | -$299.1M↓40% | -$88.0M↓46% | -$63.5M | -$81.5M↓53% | -$243.4M↓87% | -$130.3M↓8002% | -$1.6M↑98% | -$67.2M↓34% | -$50.3M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Measuring and Control Equipment
EYPT vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC.TMO | $259.4B | $700.22 | $44.6B | $6.7B | 12.6% | 0.74 | 17.4% | 1.89 | 3/9 | 3/9 | 3/7 | 1/3 | F-Score 5 | 7/11 |
| DANAHER CORP /DE/DHR | $163.9B | $233.02 | $24.6B | $3.6B | 6.9% | 0.35 | 19.1% | 1.87 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 4/11 |
| WATERS CORP /DE/WAT | $90.5B | $460.25 | $3.2B | $642.6M | 25.1% | 0.55 | 25.4% | 1.73 | 1/9 | 4/9 | 1/7 | 0/3 | F-Score 4 | 5/11 |
| AGILENT TECHNOLOGIES, INC.A | $49.0B | $173.96 | $6.9B | $1.3B | 19.3% | 0.45 | 21.3% | 1.96 | 2/9 | 5/9 | 3/7 | 1/3 | F-Score 5 | 5/11 |
| ROPER TECHNOLOGIES INCROP | $47.5B | $479.98 | $7.9B | $1.5B | 7.7% | 0.47 | 28.3% | 0.52 | 2/9 | 3/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| COHERENT CORP.COHR | $43.0B | $218.15 | $5.8B | $49.4M | 0.9% | 0.69 | 1.6% | 2.19 | 3/9 | 1/9 | 0/7 | 0/3 | F-Score 4 | 4/11 |
| TERADYNE, INCTER | $39.0B | $249.55 | $3.2B | $554.0M | 19.8% | 0.07 | 20.4% | 1.75 | 2/9 | 6/9 | 4/7 | 1/3 | F-Score 6 | 6/11 |
| ILLUMINA, INC.ILMN | $31.3B | $207.01 | $4.3B | $850.0M | 31.2% | 0.73 | 18.6% | 2.08 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |